ocrelizumab   Click here for help

GtoPdb Ligand ID: 7580

Synonyms: 2H7 | Ocrevus® | PRO70769 | RG1594
Approved drug Immunopharmacology Ligand
ocrelizumab is an approved drug (FDA (2017), EMA (2018))
Compound class: Antibody
Comment: Ocrelizumab is a humanized IgG1 anti-CD20 monoclonal antibody, approved for relapsing multiple sclerosis (RMS) and primary progressive multiple sclerosis (PPMS). This is the first therapeutic to gain approval for both of these forms of MS. Ocrelizumab is a modified version of rituximab, developed as a substitute in response to expiration of rituximab patent protection.
The submission documentation for the antibody's INN application contains the peptide sequences for the heavy and light chains of the antibody. BLAST searches of patented peptide sequences reveals identical matches with peptides claimed in patent WO2004056312, which resolve to clones 2H7.v16 and 2H7.v31 [1].
Click here for help
1. Adams CW, Chan AC, Crowley CW, Lowman HB, Nakamura GR, Presta LG. (2004)
Immunoglobulin variants and uses thereof.
Patent number: WO2004056312. Assignee: Genentech, Inc.. Priority date: 16/12/2002. Publication date: 08/07/2004.
2. Gingele S, Jacobus TL, Konen FF, Hümmert MW, Sühs KW, Schwenkenbecher P, Ahlbrecht J, Möhn N, Müschen LH, Bönig L et al.. (2018)
Ocrelizumab Depletes CD20⁺ T Cells in Multiple Sclerosis Patients.
Cells, 8 (1). [PMID:30597851]
3. Hutas G. (2008)
Ocrelizumab, a humanized monoclonal antibody against CD20 for inflammatory disorders and B-cell malignancies.
Curr Opin Investig Drugs, 9 (11): 1206-15. [PMID:18951300]
4. Kausar F, Mustafa K, Sweis G, Sawaqed R, Alawneh K, Salloum R, Badaracco M, Niewold TB, Sweiss NJ. (2009)
Ocrelizumab: a step forward in the evolution of B-cell therapy.
Expert Opin Biol Ther, 9 (7): 889-95. [PMID:19463076]
5. Montalban X, Hauser SL, Kappos L, Arnold DL, Bar-Or A, Comi G, de Seze J, Giovannoni G, Hartung HP, Hemmer B et al.. (2017)
Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis.
N Engl J Med, 376 (3): 209-220. [PMID:28002688]
6. Palanichamy A, Jahn S, Nickles D, Derstine M, Abounasr A, Hauser SL, Baranzini SE, Leppert D, von Büdingen HC. (2014)
Rituximab efficiently depletes increased CD20-expressing T cells in multiple sclerosis patients.
J Immunol, 193 (2): 580-586. [PMID:24928997]
7. Vugmeyster Y, Beyer J, Howell K, Combs D, Fielder P, Yang J, Qureshi F, Sandlund B, Kawaguchi L, Dummer W et al.. (2005)
Depletion of B cells by a humanized anti-CD20 antibody PRO70769 in Macaca fascicularis.
J Immunother, 28 (3): 212-9. [PMID:15838377]